


**Product Name** : Canertinib dihydrochloride  
**Cat. No.** : PC-42553  
**CAS No.** : 289499-45-2  
**Molecular Formula** : C<sub>24</sub>H<sub>27</sub>Cl<sub>3</sub>FN<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 558.8603  
**Target** : EGFR  
**Solubility** : 10 mM in DMSO



## Biological Activity

Canertinib dihydrochloride (CI-1033, PD183805) is a potent, irreversible, orally available **pan-ErbB** inhibitor for EGFR and ErbB2 with IC<sub>50</sub> of 7.5 nM and 9.0 nM in autophosphorylation assay.

Canertinib dihydrochloride (CI-1033, PD183805) displays no activity to PDGFR, FGFR, InsR, PKC, and CDK1/2/4.

Canertinib dihydrochloride (CI-1033, PD183805) suppresses heregulin-stimulated tyrosine phosphorylation of erbB2, erbB3 and erbB4 with IC<sub>50</sub> of 5, 14 and 10 nM, respectively, also inhibits expression of pp62c-fos in response to heregulin.

Canertinib dihydrochloride (CI-1033, PD183805) shows high in vivo activity against A431 xenografts.

## References

Smaill JB, et al. *J Med Chem.* 2000 Apr 6;43(7):1380-97.

Erlichman C, et al. *Cancer Res.* 2001 Jan 15;61(2):739-48.

Nyati MK, et al. *Clin Cancer Res.* 2004 Jan 15;10(2):691-700.

Slichenmyer WJ, et al. *Semin Oncol.* 2001 Oct;28(5 Suppl 16):80-5.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com